Aratana Therapeutics, Inc. (PETX) Analysts See $-0.17 EPS; 3 Analysts Covering Banner (BANR)

April 23, 2018 - By Vivian Currie

Banner Corporation (NASDAQ:BANR) Logo

Among 10 analysts covering Banner Corporation (NASDAQ:BANR), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Banner Corporation had 21 analyst reports since July 22, 2015 according to SRatingsIntel. Keefe Bruyette & Woods maintained the shares of BANR in report on Friday, May 26 with “Hold” rating. The company was initiated on Wednesday, September 13 by Stephens. The firm earned “Hold” rating on Friday, February 2 by Piper Jaffray. Piper Jaffray initiated Banner Corporation (NASDAQ:BANR) on Monday, September 28 with “Overweight” rating. PiperJaffray downgraded Banner Corporation (NASDAQ:BANR) on Friday, October 27 to “Neutral” rating. As per Thursday, December 21, the company rating was maintained by Keefe Bruyette & Woods. The rating was maintained by Sandler O’Neill with “Buy” on Thursday, January 25. The rating was maintained by Keefe Bruyette & Woods on Friday, July 7 with “Hold”. The stock of Banner Corporation (NASDAQ:BANR) earned “Hold” rating by Keefe Bruyette & Woods on Friday, January 26. On Friday, November 4 the stock rating was downgraded by FIG Partners to “Market Perform”. See Banner Corporation (NASDAQ:BANR) latest ratings:

02/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $58.0 Maintain
26/01/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $58.0 Maintain
25/01/2018 Broker: Sandler O’Neill Rating: Buy New Target: $62.0 Maintain
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $60.0 Maintain
27/10/2017 Broker: PiperJaffray Old Rating: Overweight New Rating: Neutral Downgrade
26/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $59.0 Downgrade
26/10/2017 Broker: DA Davidson Old Rating: Buy New Rating: Neutral Downgrade

Analysts expect Aratana Therapeutics, Inc. (NASDAQ:PETX) to report $-0.17 EPS on May, 4 before the open.They anticipate $0.17 EPS change or 50.00% from last quarter’s $-0.34 EPS. After having $-0.19 EPS previously, Aratana Therapeutics, Inc.’s analysts see -10.53% EPS growth. The stock increased 0.98% or $0.05 during the last trading session, reaching $5.13. About 51,329 shares traded. Aratana Therapeutics, Inc. (NASDAQ:PETX) has declined 14.71% since April 23, 2017 and is downtrending. It has underperformed by 26.26% the S&P500.

Banner Corporation operates as the bank holding firm for Banner Bank and Islanders Bank, which provides commercial banking and financial services and products to individuals, businesses, and public sector entities primarily in the United States. The company has market cap of $1.84 billion. It offers deposit products, including interest-bearing and non-interest-bearing checking accounts, money market deposit accounts, regular savings accounts, certificates of deposit, cash management services, and retirement savings plans. It has a 30.53 P/E ratio. The firm also provides commercial real estate loans, including owner-occupied, investment properties, and multifamily residential real estate; construction, land, and land development loans; residential mortgage loans; commercial business loans; agricultural loans; and consumer loans, such as home equity lines of credit, automobile, and boat and recreational vehicle loans, as well as loans secured by deposit accounts.

Since February 5, 2018, it had 0 buys, and 3 insider sales for $120,587 activity. 884 shares valued at $50,857 were sold by Larsen Kenneth A on Thursday, March 8. $23,756 worth of Banner Corporation (NASDAQ:BANR) was sold by Rust Steven W on Monday, March 12. On Monday, February 5 the insider PURCELL CYNTHIA D sold $45,974.

The stock increased 0.36% or $0.2 during the last trading session, reaching $56.18. About 44,132 shares traded. Banner Corporation (NASDAQ:BANR) has risen 4.20% since April 23, 2017 and is uptrending. It has underperformed by 7.35% the S&P500.

Investors sentiment decreased to 1.13 in Q4 2017. Its down 0.69, from 1.82 in 2017Q3. It is negative, as 20 investors sold Banner Corporation shares while 51 reduced holdings. 20 funds opened positions while 60 raised stakes. 28.85 million shares or 2.07% less from 29.46 million shares in 2017Q3 were reported. Us Bancshares De reported 0% in Banner Corporation (NASDAQ:BANR). State Of Tennessee Treasury Department holds 25,911 shares or 0.01% of its portfolio. New York State Common Retirement Fund owns 202,751 shares or 0.01% of their US portfolio. Schwab Charles holds 0.01% of its portfolio in Banner Corporation (NASDAQ:BANR) for 159,168 shares. First Interstate National Bank & Trust invested 0.02% of its portfolio in Banner Corporation (NASDAQ:BANR). Proshare Advisors Ltd Llc has 5,890 shares for 0% of their portfolio. Federated Invsts Inc Pa, Pennsylvania-based fund reported 3 shares. State Street has invested 0.01% in Banner Corporation (NASDAQ:BANR). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Banner Corporation (NASDAQ:BANR). Macquarie Group Ltd holds 1,400 shares. Ameriprise stated it has 0.01% in Banner Corporation (NASDAQ:BANR). Pnc Financial Group Incorporated has 0% invested in Banner Corporation (NASDAQ:BANR) for 63,111 shares. 170,682 are owned by Rmb Cap Management Limited Liability Company. Rice Hall James And Assocs has 0.58% invested in Banner Corporation (NASDAQ:BANR) for 268,736 shares. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Banner Corporation (NASDAQ:BANR) for 28,491 shares.

Investors sentiment decreased to 1.56 in Q4 2017. Its down 0.16, from 1.72 in 2017Q3. It turned negative, as 13 investors sold Aratana Therapeutics, Inc. shares while 19 reduced holdings. 21 funds opened positions while 29 raised stakes. 30.34 million shares or 3.78% less from 31.53 million shares in 2017Q3 were reported. North Star Inv Mgmt Corp owns 1,000 shares. Vanguard Gp reported 1.81 million shares. Citadel Advsrs Limited Com accumulated 68,758 shares or 0% of the stock. State Street Corp invested 0% in Aratana Therapeutics, Inc. (NASDAQ:PETX). Davenport Com Limited Liability Com reported 0.01% stake. Franklin Resources holds 0.01% or 5.94M shares. Wells Fargo And Mn holds 0% in Aratana Therapeutics, Inc. (NASDAQ:PETX) or 461,612 shares. Pdt Partners Limited Liability Corporation stated it has 0.02% of its portfolio in Aratana Therapeutics, Inc. (NASDAQ:PETX). Advisory Services Limited Com accumulated 0% or 7,000 shares. Moreover, Voya Management Ltd Liability has 0% invested in Aratana Therapeutics, Inc. (NASDAQ:PETX). Bank & Trust Of Ny Mellon invested in 0% or 144,558 shares. Campbell Inv Adviser Lc holds 11,242 shares. Stifel Fincl stated it has 14,450 shares. Pnc Services Grp Inc accumulated 1,764 shares. Bancorp Of America Corp De reported 0% of its portfolio in Aratana Therapeutics, Inc. (NASDAQ:PETX).

Among 8 analysts covering Aratana Therapeutics (NASDAQ:PETX), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Aratana Therapeutics had 22 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Friday, August 19. The firm has “Buy” rating given on Tuesday, January 16 by H.C. Wainwright. The company was maintained on Monday, March 19 by H.C. Wainwright. As per Friday, September 25, the company rating was downgraded by Craig Hallum. The firm earned “Buy” rating on Thursday, June 8 by Jefferies. The stock has “Buy” rating by Jefferies on Friday, August 4. C.L. King upgraded the shares of PETX in report on Monday, March 12 to “Buy” rating. Credit Suisse maintained Aratana Therapeutics, Inc. (NASDAQ:PETX) on Friday, March 16 with “Outperform” rating. The firm earned “Buy” rating on Friday, November 3 by Jefferies. The firm earned “Hold” rating on Monday, October 23 by Stifel Nicolaus.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. The company has market cap of $235.23 million. The Company’s product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. It currently has negative earnings. The firm markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs.

Since January 11, 2018, it had 0 insider purchases, and 2 insider sales for $250,341 activity. Shares for $158,040 were sold by TOOMAN CRAIG A on Thursday, January 11. Another trade for 19,367 shares valued at $92,301 was made by St Peter Steven on Tuesday, January 30.

Aratana Therapeutics, Inc. (NASDAQ:PETX) Ratings Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>